(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
EU Council president: Ukraine should receive binding guarantees - 2More than 3 million eye drops have been recalled from CVS, Walgreens and other national retailers. How to check if yours are safe
- 3NAFFIC and Aware to Launch First China-Europe Digital Product Passport
- 425 Years Ago, Audi's Rosemeyer Concept Was A Steampunk Supercar With A Massive Engine
- 5What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- 4 Must-Visit bar-b-que Eateries This Year
- Emotional wellness Matters: My Fight with Tension
- Top Breakfast Food: What's Your Morning Enjoyment?
- What to know about King Charles III's cancer treatment and his message to the public
- Police break up illegal chicken slaughter in Germany
- Bennu asteroid samples provide clues about solar system origins and 'space gum'
- Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- New study measures titanium in Apollo rock to uncover Moon’s early chemistry
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
